Gastric cancer and family history

Choi, Young-Wook; Kim, Nayoung

doi:10.3904/kjim.2016.147

Cited by 136 publications

(101 citation statements)

References 80 publications

(108 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In particular, gastric cancer is one of the most prominent malignant tumors in China [3]. Gastric cancer has the fifth highest incidence rate and third highest mortality rate worldwide [4], causing a great burden on public health. Oxaliplatin (OXA, Figure 1(a)) belongs to the third generation of platinum compounds used as chemotherapeutic and is gradually becoming the primary drug for the treatment of advanced gastric cancer.…”

Section: Introductionmentioning

confidence: 99%

Luteolin Suppresses the Proliferation of Gastric Cancer Cells and Acts in Synergy with Oxaliplatin

Ren

Zhang

2020

BioMed Research International

View full text Add to dashboard Cite

Objective. Gastric cancer, one of the most common malignant tumors worldwide, arises from the gastric mucosal epithelium and severely affects patient health and quality of life. Luteolin (LUT) is a flavonoid found in vegetables and fruits with diverse functions. A large number of studies have confirmed that LUT has an antitumor effect. Therefore, this study is aimed at verifying whether LUT can exert antitumor effects in synergy with oxaliplatin (OXA). As such, we examined the effects of LUT, OXA, and their coadministration in a gastric adenocarcinoma cell line (SGC-7901). We used the MTT assay to quantify the proliferation of SGC-7901 cells, flow cytometry to detect the cell cycle and apoptosis, ELISA to detect the expression of cell-cycle-related proteins, and western blot to detect the expression of related apoptotic factors. The results of this study show that the combination of LUT and OXA inhibited SGC-7901 cell proliferation and induced apoptosis by altering cell-cycle proportions. In addition, the combination also activated Cyt c/caspase signaling in SGC-7901 cells. In summary, LUT synergy with OXA inhibited the proliferation of gastric cancer cells in vitro. The present study also elucidated the mechanism by which LUT potentiated the sensitivity of SGC-7901 cells to OXA through the Cyt c/caspase pathway.

show abstract

Section: Introductionmentioning

confidence: 99%

Luteolin Suppresses the Proliferation of Gastric Cancer Cells and Acts in Synergy with Oxaliplatin

Ren

Zhang

2020

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Although familial aggregation is found in about 10% of GC cases [25], the incidence of CDH1 alterations in patients with or without family history of GC is unclear. We explored CDH1 alterations with NGS and investigated the association with family history in 993 GC patients.…”

Section: Discussionmentioning

confidence: 99%

“…Although familial aggregation is found in about 10% of GC cases, the prevalence of CDH1 alterations in patients with familial aggregation is unclear [25].…”

mentioning

confidence: 99%

CDH1 mutations in gastric cancers are not influenced by family history

Choi¹,

Jang²,

Heo³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: CDH1 mutation is the most frequent genetic alteration in hereditary diffuse gastric cancer (GC) and early onset diffuse GC patients. However, the incidence of CDH1 mutations in sporadic GC with or without family history has not been studied. Methods: This retrospective study includes a total of 993 Korean patients with primary advanced GC who underwent surgery and received palliative chemotherapy. Targeted deep sequencing was performed in all cases and family history of GC was searched with survival analysis. Results: We found CDH1 alterations in 146 of 993 patients (14.7%) and 8 were germline (0.8%). Out of 146 patients with CDH1 mutations, 25 (17.1%) had a family history of GC in one of their first relatives, and 12 patients (8.2%) were diagnosed with familial GC (FGC). All cases with FGC were diffuse type by Lauren classification, and only one harbored a previously reported germline mutation of CDH1 (c.2638G>A) and the remaining 11 harbored known somatic CDH1 mutations. Among all patients with CDH1 mutation, there was no significant survival difference between patients with family history or FGC. In the 847 patients without CDH1 mutation, 189 (22.3 %) had a family history of GC and 92 patients (10.9%) were FGC. CDH1 mutations were more frequent in patients with early onset (<45 years) GC (45.5%) compared with patients with late onset GC (10.9%) (p = 0.001), but were not significantly associated with the family history of GC (p > 0.05). Conclusions: CDH1 mutations are mostly somatic and typically are not associated with family history.

show abstract

“…Nevertheless, there is accumulating evidence to support that genetic factors play an important role in its pathogenesis. Firstly, numerous genetic loci have been found to be associated with an increased risk of GC. Secondly, family clustering of GC is not uncommon, and positive family history in first‐degree relatives has also been proved to be a strong independent risk factor of GC . Overall, these findings jointly indicate that genetic predisposition to GC is crucial for its occurrence and development.…”

Section: Introductionmentioning

confidence: 95%

Associations between interleukin gene polymorphisms and the risk of gastric cancer: A meta‐analysis

Wang

Yao

et al. 2018

Clin Exp Pharma Physio

View full text Add to dashboard Cite

Gastric cancer (GC) refers to malignancy that occurs in the stomach. It is the most common malignant tumour in the digestive tract, and the leading cause of cancer-related mortality worldwide. 1 Despite rapid advances in early diagnosis and surgical treatments in the past few decades, the 5-year relative survival rate of GC is still below 30%. 2 So far, the pathogenic mechanism of GC is still largely unknown. Nevertheless, there is accumulating evidence to support that genetic factors play an important role in its pathogenesis. Firstly, numerous genetic loci have been found to be associated with an increased risk of GC. 3-5 Secondly, family clustering of GC is not uncommon, and positive family history in first-degree relatives has also been proved to be a strong independent risk factor of GC. 6Overall, these findings jointly indicate that genetic predisposition to GC is crucial for its occurrence and development.It has been well established that immune dysfunction is implicated in the pathogenesis of GC. Firstly, it was found that suppressor T cells were increased while cytotoxic T cells were decreased in GC patients. 7 Secondly, several pilot studies have demonstrated that immune-stimulatory therapy could result in disease regression and prolonged survival in GC patients. 8,9 As a result, certain gene polymorphism in regulators of anti-tumour immune responses were thought to be implicated in the development of GC. Recently, many genetic association studies have been carried out to investigate the potential roles of interleukin-2 (IL-2), IL-4, IL-6 and IL-8 gene polymorphisms in GC, however, the results of these studies Summary Recently, the roles of interleukin-2 (IL-2), IL-4, IL-6 and IL-8 gene polymorphisms in gastric cancer (GC) have been studied extensively, with conflicting results. Therefore, we conducted the present meta-analyses to better elucidate the roles of interleukin gene polymorphisms in GC. Eligible articles were searched in PubMed, MEDLINE,Embase, Web of Science and CNKI. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to detect any potential association between interleukin gene polymorphisms and the risk of GC. A total of 63 case-control studies was finally included in our analyses. Significant associations with the risk of GC were detected for the IL-6 rs1800796 and IL-8 rs4073 polymorphisms in overall analyses. Further subgroup analyses based on ethnicities of participants revealed that the IL-4 rs2243250, IL-6 rs1800796 and IL-8 rs4073 polymorphisms were significantly associated with the risk of GC in Asians. Moreover, IL-8 rs4073 polymorphism was also significantly associated with the risk of GC in Africans. In conclusion, our findings suggested that IL-4 rs2243250, IL-6 rs1800796 and IL-8 rs4073 polymorphisms may serve as genetic biomarkers of GC. K E Y W O R D Sgastric cancer, gene polymorphisms, interleukin, meta-analysis

show abstract

Gastric cancer and family history

Cited by 136 publications

References 80 publications

Luteolin Suppresses the Proliferation of Gastric Cancer Cells and Acts in Synergy with Oxaliplatin

Luteolin Suppresses the Proliferation of Gastric Cancer Cells and Acts in Synergy with Oxaliplatin

CDH1 mutations in gastric cancers are not influenced by family history

Associations between interleukin gene polymorphisms and the risk of gastric cancer: A meta‐analysis

Contact Info

Product

Resources

About